Medarex Inc. could receive up to $530 million through a deal to partner a Phase III metastatic melanoma product with Bristol-Myers Squibb Co. (BioWorld Today)
Medarex Inc. could receive up to $530 million through a deal to partner a Phase III metastatic melanoma product with Bristol-Myers Squibb Co. (BioWorld Today)
The Cambridge, Mass.-based company entered an agreement with Wyeth Pharmaceuticals to buy back rights for the osteoarthritis product in the U.S. and five European countries. As a result, Genzyme will receive all end-user revenue in those territories for Synvisc (hylan G-F 20), the top-selling viscosupplementation product for pain due to osteoarthritis of the knee in the U.S. and Canada. (BioWorld Today)
